Blogs
News
-
Collaborations | 19 Dec, 2025
Porton Advanced’s End-to-End Cell Therapy CDMO Service Accelerates NMPA Approval of Gene MiNK Biotechnology’s Innovative NK Therapy
-
Collaborations | 12 Dec, 2025
Gene MiNK Biotechnology’s Innovative BCMA-targeted CAR-NK Therapy Secures NMPA IND Approval, Accelerated by Porton Advanced’s Comprehensive End-to-End Cell Therapy CDMO Service












